Clearpoint Neuro, INC Form 4 insider transactions

ClearPoint Neuro, Inc. Director Lynnette C. Fallon was granted 12,417 restricted stock units (RSUs) as part of her compensation, aligning her interests with shareholders.

ClearPoint Neuro, Inc. Director R. John Fletcher was granted 12,417 restricted stock units as part of his compensation, vesting over approximately one year.

ClearPoint Neuro, Inc. announced that Director Pascal E. R. Girin was granted 12,417 restricted stock units, aligning his interests with shareholders.

ClearPoint Neuro, Inc. Director B. Kristine Johnson was granted 12,417 restricted stock units, which will vest based on time or the company's 2026 annual meeting.

ClearPoint Neuro, Inc. Director Matthew B. Klein was granted 12,417 Restricted Stock Units as part of his compensation, aligning his interests with shareholders.

ClearPoint Neuro, Inc. Director Linda M. Liau was granted 12,417 restricted stock units (RSUs) on May 22, 2025, as part of her compensation.

ClearPoint Neuro, Inc. director Timothy T. Richards was granted 12,417 restricted stock units, which will vest based on future performance or time, aligning his interests with shareholders.

Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., converted 21,093 restricted stock units into common stock on May 16, 2025.

Director R. John Fletcher settles 21,093 restricted stock units into common stock of ClearPoint Neuro, Inc.

Director Lynnette C. Fallon settled restricted stock units for shares of ClearPoint Neuro common stock on May 16, 2025.

B. Kristine Johnson, a director at ClearPoint Neuro, Inc., settled 21,093 restricted stock units for common stock on May 16, 2025.

Matthew Klein, a director at ClearPoint Neuro, settled 21,093 restricted stock units into common stock on May 16, 2025.

Director Linda M. Liau settled 21,093 restricted stock units into common stock of ClearPoint Neuro, Inc. on May 16, 2025.

Director Timothy Richards settled 21,093 restricted stock units into common stock of ClearPoint Neuro, Inc.

Director R. John Fletcher acquired 486 shares of ClearPoint Neuro, Inc. common stock on April 1, 2025, as part of the company's Non-Employee Director Compensation Plan.

Director Timothy T. Richards acquired 938 shares of ClearPoint Neuro, Inc. common stock on April 1, 2025, as payment for director fees.

Director Pascal E. R. Girin acquires 525 shares of ClearPoint Neuro, Inc. common stock as payment for director fees.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, reports the acquisition and disposal of common stock related to the settlement of restricted stock units.

Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., settled restricted stock units for shares and disposed of shares to cover tax obligations on March 12, 2025.

Danilo D'Alessandro, CFO of ClearPoint Neuro, settled restricted stock units and sold shares to cover tax obligations on March 12, 2025.

ClearPoint Neuro CEO Joseph Michael Burnett reports the acquisition and disposal of common stock and restricted stock units.

ClearPoint Neuro's Chief Business Officer, Jeremy L. Stigall, reports the vesting and sale of shares to cover tax obligations.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition and disposal of common stock and restricted stock units.

L. Jeremy Stigall, Chief Business Officer of ClearPoint Neuro, settled restricted stock units for common stock and disposed of shares to cover tax obligations.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, reports the acquisition and disposal of common stock and settlement of restricted stock units on March 6, 2025.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition and disposal of common stock and restricted stock units on March 6, 2025.

ClearPoint Neuro's CEO, Joseph Burnett, reports the settlement of restricted stock units and shares withheld for tax obligations.

Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., was granted 44,280 restricted stock units on March 3, 2025, which vest over a three-year period.

ClearPoint Neuro's Chief Operating Officer, Mazin Sabra, received 33,210 restricted stock units (RSUs) on March 3, 2025, vesting over a three-year period.

ClearPoint Neuro's CFO, Danilo D'Alessandro, reports the acquisition of 51,660 restricted stock units (RSUs) that vest over a three-year period.